Sep

    Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

    Hogan Lovells, 12 PM EDT

    Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World. In the wake of FTC v. Actavis and the European Commission's decisions against Lundbeck, J&J, and Novartis, pharma patent settlement agreements remain an issue in the US and Europe. Among questions yet to be resolved is how co-promotion and co-marketing, and manufacturing arrangements that are part of patent settlement agreements should be analyzed by antitrust enforcers.

    Moderators

    • Lauren Battaglia, Hogan Lovells

     Speakers:

    • Mark Ford, Wilmer Hale
    • Barry Harris, Economists Inc.
    • Heather Johnson, FTC
    • Jacob Westin, GlaxoSmithKline

    FREE
    Antitrust Section Members,
    Government, Non-profit Employees,
    Students

    $25 Other Non-Members


    Explore Section benefits or call
    800-285-2221 to join. Code RAT14IP25.
     
     

    For this and all upcoming events visit http://AmBar.org/ATEvents.
     
    CLE
    The ABA is not seeking CLE credit for this program. 
    Audio Archive

    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

    $25
    NON-MEMBERS
    $25
    MEMBERS
    $0
    SECTION MEMBERS
    Register Now *Additional discounts may apply at checkout

    Log In to view your rate

    Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

    Event Details

    Format

    Teleconference

    Date

    Sep 04, 2014

    2014-09-04T12:00:00-04:00 2014-09-04T13:30:00-04:00 Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

    Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World. In the wake of FTC v. Actavis and the European Commission's decisions against Lundbeck, J&J, and Novartis, pharma patent settlement agreements remain an issue in the US and Europe. Among questions yet to be resolved is how co-promotion and co-marketing, and manufacturing arrangements that are part of patent settlement agreements should be analyzed by antitrust enforcers.

    Moderators

    • Lauren Battaglia, Hogan Lovells

     Speakers:

    • Mark Ford, Wilmer Hale
    • Barry Harris, Economists Inc.
    • Heather Johnson, FTC
    • Jacob Westin, GlaxoSmithKline

    FREE
    Antitrust Section Members,
    Government, Non-profit Employees,
    Students

    $25 Other Non-Members


    Explore Section benefits or call
    800-285-2221 to join. Code RAT14IP25.
     
     

    For this and all upcoming events visit http://AmBar.org/ATEvents.
     
    CLE
    The ABA is not seeking CLE credit for this program. 
    Audio Archive

    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

    Hogan Lovells

    Sponsors

    Section of Antitrust Law

    Related Products

    Related On-Demand CLE